Results for activity of plasma cells translation from Danish to Portuguese

on community statistics and activity of foreign affiliates
on community statistics and activity of foreign affiliates

safety and supply of plasma - derived medicinal products
safety and supply of plasma - derived medicinal products

clinical investigation of plasma derived factor viii and ix products
clinical investigation of plasma derived factor viii and ix products

note for guidance on the clinical investigation of plasma derived antithrombin products
investigation of plasma derived antithrombin products

(17) another important activity of the racing sector is horsebreeding.
(17) another important activity of the racing sector is horsebreeding.

titel på dokumentet note for guidance on the clinical investigation of plasma derived antithrombin products
título note for guidance on the clinical investigation of plasma derived antithrombin products

the aim of the proposed regulation is to establish common rules for the production of community statistics on the structure and activity of foreign affiliates .
the aim of the proposed regulation is to establish common rules for the production of community statistics on the structure and activity of foreign affiliates .

for outward fats , resident owners should supply information on the activity of their affiliates located in extra-eu countries .
for outward fats , resident owners should supply information on the activity of their affiliates located in extra-eu countries .

titel på dokumentet note for guidance on the clinical investigation of plasma derived fibrin sealants note for guidance on the clinical investigation of von willebrand factor warning on transmissible agents for patient leaflets and spcs core spc for plasma derived fibrin sealants
grupo de trabalho "produtos derivados do sangue" do cpmp título note for guidance on the clinical investigation of plasma derived fibrin sealants note for guidance on the clinical investigation of von willebrand factor warning on transmissible agents for patient leaflets and spcs core spc for plasma derived fibrin sealants

contribution to part s. 2. 3 of the structure of the dossier for applications for marketing authorisation – control of starting materials for the production of plasma- derived medicinal products
contribution to part s. 2. 3 of the structure of the dossier for applications for marketing authorisation – control of starting materials for the production of plasma- derived medicinal products

impact assessment form the impact of the proposal on business with special reference to small and medium-sized enterprises ( smes ) title of proposal proposal for a regulation of the european parliament and the council on community statistics on the structure and activity of foreign affiliates .
impact assessment form the impact of the proposal on business with special reference to small and medium-sized enterprises ( smes ) title of proposal proposal for a regulation of the european parliament and the council on community statistics on the structure and activity of foreign affiliates .

titel på dokumentet note for guidance on the clinical investigation of plasma derived antithrombin products core summary of product characteristics for plasma- derived antithrombin products note for guidance on the clinical investigation of human normal immunoglobulin for intramuscular and subcutaneous use core summary of product characteristics for human normal immunoglobulin for intramuscular and subcutaneous use note for guidance on the clinical investigation of plasma derived fibrin sealants core summary of product characteristics for plasma derived fibrin sealants note for guidance on the clinical investigation of von willebrand factor core summary of product characteristics for von willebrand factor note for guidance on the clinical investigation of alpha1 antitrypsin core summary of product characteristics for alpha1 antitrypsin core summary of product characteristics for the following specific immunoglobulins:
título note for guidance on the clinical investigation of plasma derived antithrombin products core summary of product characteristics for plasma- derived antithrombin products note for guidance on the clinical investigation of human normal immunoglobulin for intramuscular and subcutaneous use core summary of product characteristics for human normal immunoglobulin for intramuscular and subcutaneous use note for guidance on the clinical investigation of plasma derived fibrin sealants core summary of product characteristics for plasma derived fibrin sealants note for guidance on the clinical investigation of von willebrand factor core summary of product characteristics for von willebrand factor note for guidance on the clinical investigation of alpha1 antitrypsin core summary of product characteristics for alpha1 antitrypsin core summary of product characteristics for the following specific immunoglobulins: